Listas Anotadas de Medicamentos e Dispositivos

Linezolid

Injection for intravenous administration 2 mg/mL in 300 mL bag Injection for intravenous administration 2 mg/mL Powder for oral liquid 100 mg/5 mL. Tablet 600 mg Tablet 400 mg Tablet (dispersible) 150 mg

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	6.2.3 Reserve group antibiotics	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
PAHO Strategic Fund Medicine List	2.4. Antiberculosis med. 2nd line	Sem observações

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	6.2.3 Reserve group antibiotics	Sem observações
WHO Model List of Essential Medicines (2021)	6.2.5. Antituberculosis medicines	Outras observações: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.

Este medicamento esta presente em:

Listas	Seção	Observação
Cuba	6.2.9 Otros antimicrobianos	Sem observações
WHO Model List of Essential Medicines (2021)	6.2.3 Reserve group antibiotics	Sem observações
WHO Model List of Essential Medicines (2021)	6.2.5. Antituberculosis medicines	Outras observações: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.
PAHO Strategic Fund Medicine List	2.4. Antiberculosis med. 2nd line	Outras observações: Procurement of this medicine through the Strategic Fund should be limited for use according to WHO recommended M/XDR-TB regimen in patients for whom there are few or no treatments available. Patients receiving this medicine should be monitored for potential adverse events or related toxicities through national pharmacovigilance programs and data from the WHO Programme for International Drug Monitoring (UPPSALA).

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	6.2.3 Reserve group antibiotics	Sem observações
PAHO Strategic Fund Medicine List	2.4. Antiberculosis med. 2nd line	Outras observações: Procurement of this medicine through the Strategic Fund should be limited for use according to WHO recommended M/XDR-TB regimen in patients for whom there are few or no treatments available. Patients receiving this medicine should be monitored for potential adverse events or related toxicities through national pharmacovigilance programs and data from the WHO Programme for International Drug Monitoring (UPPSALA).

Este medicamento esta presente em:

Listas	Seção	Observação
WHO Model List of Essential Medicines (2021)	6.2.5. Antituberculosis medicines	Este medicamento requer um especialista para uso em crianças Outras observações: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.
PAHO Strategic Fund Medicine List	2.4. Antiberculosis med. 2nd line	Sem observações

Recursos de Informação: Linezolid

Nenhuma informação disponível